Delving into the Latest Updates on Mequitazine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Butix, Histacoid, Mequitazine (JP17/INN)

+ [15]

Target

H1 receptor

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [3]

Active Indication

Conjunctivitis, AllergicAsthmaDermatitis+ [5]

Inactive Indication-

Originator Organization

Active Organization

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (07 Oct 1982),

DermatitisEczemaPruritus+ [2]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC20H22N2S

InChIKeyHOKDBMAJZXIPGC-UHFFFAOYSA-N

CAS Registry29216-28-2

In UK military veterans (P) the remotely delivered Fast Imagery Reversal Script for Trauma release Protocol (I), compared to waiting list control (C) is clinically and statistically effective in reducing post-traumatic stress disorder symptoms by the minimal clinically important difference (O) at 20 weeks (T)

Start Date01 Mar 2025

Sponsor / Collaborator

King's College London

ITMCTR2024000148

/ SuspendedNot ApplicableIIT

Clinical study on the effect of Sublumbilical camp under the needle knife release on neurogenic bladder function after spinal cord injury

Start Date01 Nov 2024

Sponsor / Collaborator-

CTRI/2024/10/075516

/ Not yet recruitingNot ApplicableIIT

Influence of Myofascial Release and Remote Myofascial Release on Gait and Muscle Activation In Asymptomatic Hamstring Muscle Tightness - NIL

Start Date28 Oct 2024

Sponsor / Collaborator

Jamia Millia Islamia

100 Clinical Results associated with Mequitazine

Login to view more data

100 Translational Medicine associated with Mequitazine

Login to view more data

100 Patents (Medical) associated with Mequitazine

Login to view more data

145

Literatures (Medical) associated with Mequitazine

04 Nov 2024·Chemistry – A European Journal

Overriding Cage Effect in Electron Donor‐Acceptor Photoactivation of Diaryliodonium Reagents: Synthesis of Chalcogenides

Article

Author: Murarka, Sandip ; Mahapatra, Sanat Kumar ; Parida, Sushanta Kumar ; Roy, Lisa ; Meher, Prahallad

AbstractIn recent times, diaryliodonium reagents (DAIRs) have witnessed a resurgence as arylating reagents, especially under photoinduced conditions. However, reactions proceeding through electron donor‐acceptor (EDA) complex formation with DAIRs are restricted to electron‐rich reacting partners serving as donors due to the well‐known cage effect. We discovered a practical and high‐yielding visible‐light‐induced EDA platform to generate aryl radicals from the corresponding DAIRs and use them to synthesize key chalcogenides. In this process, an array of DAIRs and dichalcogenides react in the presence of 1,4 diazabicyclo[2.2.2]octane (DABCO) as a cheap and readily available donor, furnishing a variety of di(hetero)aryl and aryl/alkyl chalcogenides in good yields. The method is scalable, features a broad scope with good yields, and operates under open‐to‐air conditions. The photoinduced chalcogenation technology is suitable for late‐stage functionalizations and disulfide bioconjugations and facilitates access to biologically relevant thioesters, dithiocarbamates, sulfoximines, and sulfones. Moreover, the method applies to synthesizing diverse pharmaceuticals, such as vortioxetine, promazine, mequitazine, and dapsone, under amenable conditions.

30 Dec 2023·European Journal of General Practice

Immediate release fentanyl in general practices: Mostly off-label prescribing

Article

Author: Weesie, Yvette M. ; van Dijk, Liset ; Hek, Karin ; Bouvy, Marcel L.

BACKGROUNDThe immediacy of the onset of opioids may be associated with the risk of dependency and accidental overdose. Nasal and oromucosal fentanyl dosage forms are so called immediate release fentanyl (IRF). These IRFs have been approved to treat breakthrough pain in patients with cancer who are on chronic opioid treatment only. There are signals of increased off-label prescribing of IRFs in general practices.OBJECTIVESThis study aims to provide insight into the frequency of IRF prescription in Dutch general practices and the extent to which IRF is prescribed off-label.METHODSRoutinely collected electronic health records of general practices (GPs) participating in Nivel Primary Care Database were used. Adult patients with IRF prescriptions in 2019 were selected from whom dispensing data on 2018 and 2019 was available. Diagnoses were recorded by GPs using International Classification of Primary Care. Descriptive analyses were performed.RESULTSThis study included 342 GPs with a patient population of 1,297,942 patients, 1,368 patients received at least one IRF prescription in 2019, which is equal to 1.1 patients per 1,000 registered patients. Most patients (74.9%) with an IRF prescription received an off-label prescription. A slight majority had a cancer diagnosis but nearly 65.2% did not have a maintenance therapy and 14% were opioid-naive before receiving their first IRF prescription.CONCLUSIONIRFs are not prescribed frequently in Dutch general practices. However, when prescribed, a relatively large portion of patients received an off-label prescription.

01 Aug 2021·ELECTROPHORESISQ3 · BIOLOGY

Chiral separation and molecular simulation study of six antihistamine agents on a coated cellulose tri‐(3,5‐dimethylphenycarbamate) column (Chiralcel OD‐RH) and its recognition mechanisms

Q3 · BIOLOGY

Article

Author: Guo, Xingjie ; Yu, Jia ; Liu, Yanru ; Wang, Xia

AbstractEnantiomeric separation of six antihistamine agents was first systematically investigated on a cellulose‐based chiral stationary phase (CSP), that is, cellulose tris‐(3,5‐dimethyl phenyl carbamate) (Chiralcel OD‐RH), under the reversed‐phase mode. Orphenadrine, meclizine, terfenadine, dioxopromethazine, and carbinoxamine enantiomers were completely separated under the optimized mobile phase conditions with resolutions of 5.02, 1.93, 1.68, 1.67, and 1.54, respectively. Mequitazine was partially separated with a resolution of 0.77. The influences of type and concentration of buffer salt, the pH of buffer solution, and the type and ratio of organic modifier on the chiral separation were evaluated and optimized. For a better insight into the enantiorecognition mechanisms, molecular docking was carried out via the Autodock software. The lowest binding energy and the optimal conformations of the analytes/CSP complexes were supplied, and the mechanisms of chiral recognition were determined. According to the results, the key interactions for the chiral recognition of these six analytes on CDMPC were π–π interactions, hydrophobic interactions, hydrogen bond interactions, and some special interactions.

100 Deals associated with Mequitazine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01324	Mequitazine	R06AD07	DB01071

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Conjunctivitis, Allergic	NZ	-	09 Jul 1999
Asthma	JP	Alfresa Pharma Corp.	30 Mar 1990
Asthma	JP	Asahi Kasei Corp.	30 Mar 1990
Dermatitis	JP	Asahi Kasei Corp.	07 Oct 1982
Eczema	JP	Asahi Kasei Corp.	07 Oct 1982
Pruritus	JP	Asahi Kasei Corp.	07 Oct 1982
Pruritus	JP	Alfresa Pharma Corp.	07 Oct 1982
Rhinitis, Allergic	JP	Asahi Kasei Corp.	07 Oct 1982
Rhinitis, Allergic	JP	Alfresa Pharma Corp.	07 Oct 1982
Urticaria	JP	Asahi Kasei Corp.	07 Oct 1982
Urticaria	JP	Alfresa Pharma Corp.	07 Oct 1982
Rhinitis	-	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2023	Not Applicable	Vaso-occlusive crisis	200	Immediate-Release (IR) opioids	vojmghhaxk(xdagsrzucz) = xtzdynbznc aonxtsjvqx (euadjbzzfa )	-	10 Dec 2023
				Extended-Release (ER) opioids	vojmghhaxk(xdagsrzucz) = dybrxatkil aonxtsjvqx (euadjbzzfa )
DDW2022	Not Applicable	Metabolic Diseases	-	highly functional duodenal stent with controlled radical oxygen species release (Control group (no PDT stent))	bvbvgfbaeb(towdxrwnju) = PDT was applied with no evidence of early stricture, pancreatitis, or hemorrhage in all 8 pigs gyzgpoyxpn (roehqrxvbp ) View more	-	21 May 2022
MO1009 (ERA2022)	Not Applicable	Delayed renal graft function	-	Immediate-Release Tacrolimus (IR-Tac)	(apkxtfgjvf) = kavotiaxao lgnmrqlbmh (pcviakghpc )	Positive	03 May 2022
				LCP-Tac (LCPT)	(apkxtfgjvf) = vjyuskgfvm lgnmrqlbmh (pcviakghpc )
ASTRO2020	Not Applicable	Neoplasms	-	Nanoparticle-Mediated Radiation-Triggered Release Of Nitrate (AuNP@nIm-CPP)	ifwowkegjs(gsylzmzckv) = aexhaigcxo aoocucchfw (wefhbualis )	-	01 Nov 2020
				Nanoparticle-Mediated Radiation-Triggered Release Of Nitrate (AuNP@CPP)	ifwowkegjs(gsylzmzckv) = hxjzhhgpkv aoocucchfw (wefhbualis )
TRANSFORM study (ERA2020)	Not Applicable	Renal transplant rejection	38	Twice-daily Tacrolimus (TAC-IR) + Everolimus (EVR) + Corticosteroid	wfqnfhstnd(dpjacnnklv) = thcmffogpa ifnrqsushr (lfcycczcjy, 6.4 - 9.5) View more	Positive	06 Jun 2020
				Once-daily Extended Release Tacrolimus (LCPT) + Everolimus (EVR) + Corticosteroid	wfqnfhstnd(dpjacnnklv) = xkxqggubra ifnrqsushr (lfcycczcjy, 5.4 - 8.7) View more
WCN2019	Not Applicable	REM Sleep Behavior Disorder First line	40	Prolonged-release melatonin 2mg	qglwlaxqsh(ozfckbkxjr) = bhngoebvlc cwontmoemw (ynpwssbnhy )	-	15 Oct 2019
				Clonazepam 0.5mg	qglwlaxqsh(ozfckbkxjr) = zxbbhxnixt cwontmoemw (ynpwssbnhy )
PO115 (AAO2019)	Not Applicable	Keratitis Maintenance	-	Novel In Situ Sustained-Release Drug Delivery System	uhvdmtiegj(pucgpzcpgt) = ryauvfvoii rbgvgxslpc (pxumlgaipf )	Positive	12 Oct 2019
ERA2018	Not Applicable	-	-	Extended Release Tacrolimus (LCPT-ER)	(qgxwoogkgy) = hfldzwxuov wpolrnchtm (jzdvetasie ) View more	-	18 May 2018
				Immediate-Release Tacrolimus (TAC-IR)	(qgxwoogkgy) = idcpgedvkc wpolrnchtm (jzdvetasie )
NCT00934661 (CTgov)	Phase 4	-	40	Extended Release Epidural Morphine (EREM) (Extended Release Epidural Morphine)	bjckvduzzh(hsqpxhndbn) = erkqmqusiv uafidaktgz (sdfqszdpxv, ejrwemnsgh - uozqifylmx) View more	-	16 Jan 2018
				Placebo (Placebo Group)	bjckvduzzh(hsqpxhndbn) = bmnobflmms uafidaktgz (sdfqszdpxv, bfsgqdqqbn - nnrpgcybtx) View more
CNS2015	Not Applicable	Attention Deficit Disorder With Hyperactivity	45	Methylphenidate Extended-Release Oral Suspension (MEROS)	fxqjtyeoqj(anhcngupnk) = kgxvhxyolr knadlszyvn (svhjmixwqw ) View more	Positive	25 Sep 2015